Source:http://linkedlifedata.com/resource/pubmed/id/12357360
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2002-10-1
|
pubmed:abstractText |
ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous ((32)P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the long-term safety of hydroxyurea (HU). Pipobroman (PI), a well tolerated and simple to use drug, constitutes a valid alternative to those cytoreductive treatments. The present study reports on 155 ET patients treated at our institution from 1985 to 1995, and monitored until December 2000. A good control of thrombocytosis was achieved with PI as the only treatment in 106 patients and with HU in 23 patients. Twenty-six patients received no treatment. After a median follow-up of 104 months, seven patients (four treated with HU, and three with PI) developed AML whereas one patient treated with PI developed MDS. A significant difference in progression-free survival was observed between HU- and PI-treated patients (P = 0.004). A short-arm deletion of chromosome 17 was most frequently detected in HU-treated patients, while a long-arm trisomy of chromosome 1 and a monosomy 7q were seen in PI-treated patients. No TP53 mutation was discovered in the six patients studied (two HU-treated and four PI-treated). We conclude that these cytogenetic abnormalities are not linked to the natural history of the disease, but rather that they might be induced by the cytoreductive treatment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0887-6924
|
pubmed:author |
pubmed-author:BernasconiCC,
pubmed-author:BernasconiPP,
pubmed-author:BoniMM,
pubmed-author:BrusamolinoEE,
pubmed-author:CalatroniSS,
pubmed-author:CaresanaMM,
pubmed-author:CaviglianoP MPM,
pubmed-author:GiardinoCC,
pubmed-author:LazzarinoMM,
pubmed-author:PassamontiFF,
pubmed-author:PistorioAA,
pubmed-author:RoccaBB,
pubmed-author:VolpeGG
|
pubmed:issnType |
Print
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2078-83
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:12357360-Acute Disease,
pubmed-meshheading:12357360-Adolescent,
pubmed-meshheading:12357360-Adult,
pubmed-meshheading:12357360-Aged,
pubmed-meshheading:12357360-Aged, 80 and over,
pubmed-meshheading:12357360-Chromosome Aberrations,
pubmed-meshheading:12357360-Female,
pubmed-meshheading:12357360-Humans,
pubmed-meshheading:12357360-Hydroxyurea,
pubmed-meshheading:12357360-In Situ Hybridization, Fluorescence,
pubmed-meshheading:12357360-Leukemia, Myeloid,
pubmed-meshheading:12357360-Male,
pubmed-meshheading:12357360-Middle Aged,
pubmed-meshheading:12357360-Pipobroman,
pubmed-meshheading:12357360-Polymerase Chain Reaction,
pubmed-meshheading:12357360-Polymorphism, Single-Stranded Conformational,
pubmed-meshheading:12357360-Thrombocythemia, Essential
|
pubmed:year |
2002
|
pubmed:articleTitle |
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
|
pubmed:affiliation |
Department of Blood, Heart and Lung Medical Sciences of the University of Pavia and Division of Hematology, Policlinico San Matteo IRCCS, Italy.
|
pubmed:publicationType |
Journal Article
|